Short answer
Lexeo Therapeutics, Inc. (LXEO) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 references earnings-related disclosure but provides no operating results or financial figures.
Lexeo Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 references earnings-related disclosure but provides no operating results or financial figures
- Investors must review the accompanying exhibit for the fiscal-year 2026 results and management commentary
Item 8.01 · Other Events
- Updated corporate presentation signals refreshed investor messaging and potentially revised strategic priorities
- Exhibit 99.2 contains the substantive disclosures for investor and analyst review
Item EX-99.1 · Exhibit EX-99.1
- LX2006 pivotal SUNRISE-FA 2 initiated with first patient enrolled in June; topline data targeted for second half of 2027
- Potential accelerated-approval BLA submission targeted for first half of 2028, subject to FDA alignment and trial execution
- FDA RMAT designation for LX2020 strengthens regulatory interaction and potential expedited development in PKP2-ACM
- Cash, equivalents and investments $234.2M, expected to fund operations into 2028; liquidity supports planned clinical milestones
- Q2 R&D expense $19.0M versus $14.7M; net loss $25.9M or $0.30 per share versus $26.1M or $0.60 per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lexeo Therapeutics, Inc. 8-K filings
Get the next LXEO 8-K as it lands
Follow LXEO for push alerts, or ask the research agent what this filing means.